T7 RNA POLYMERASE VARIANTS WITH ENHANCED THERMOSTABILITY

The present invention provides improved variants of T7 RNA polymerase by introducing novel mutations which lead to improved thermostability of the enzyme. According to the invention, amino acid substitutions at the positions Val426, Ser633, Val650, Thr654, Ala702, Val795, and combinations thereof are advantageous.

Skip to: Description  ·  Claims  · Patent History  ·  Patent History
Description
RELATED APPLICATIONS

This application claims priority to European application EP 10004059.1 filed Apr. 16, 2010.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 17, 2011, is named 26576US.txt, and is 297,574 bytes in size.

FIELD OF THE INVENTION

The invention pertains to the field of biochemistry, particularly to the field of enzyme engineering.

The present invention provides improved variants of T7 RNA polymerase by introducing novel mutations which lead to improved thermostability of the enzyme. According to the invention, amino acid substitutions at the positions Val426, Ser633, Val650, Thr654, Ala702, Val795, and combinations thereof are advantageous.

BACKGROUND OF THE INVENTION

T7 RNA polymerase (E.C. 2.7.7.6.; herein also referred to as “T7 polymerase” or “T7”) is a monomeric bacteriophage encoded DNA directed RNA polymerase which catalyzes the formation of RNA in the 5′→3′ direction. In the process of initiation of transcription T7 recognizes a specific promoter sequence, the T7 promoter. T7 consists of 883 amino acids and has a molecular weight of 99 kDa. On the level of amino acid sequence T7 is highly homologous to T3 RNA polymerase and, to a lesser extent, SP6 RNA polymerase. The three-dimensional structure of T7 is very similar to other polymerases with different template and substrate specificities, despite low sequence similarity. T7 consists of different domains, the N-terminal domain, the “thumb”, the “palm” and the “fingers” (Sousa, R., and Mukherjee, S., Prog. Nucl. Acid Res. Mol. Biol. 73 (2003) 1-41).

Detailed studies of the transcription reaction showed that the enzyme acts like a molecular machine showing well concerted movements of flexible parts of the enzyme (Steitz, T. A., EMBO J. 25 (2006) 3458-3468; Steitz, T. A., Curr. Opin. Struct. Biol. 14 (2004) 4-9; Yin, Y. W., and Steitz, T. A., Cell 116 (2004) 393-404).

Several structures of T7 in complex with promoter DNA were solved and are available in the Protein Data Bank (pdb). The structure of the initiation complex of T7 RNA polymerase was solved at high resolution (Cheetham, G. M. T., et al., Nature 399 (1999) 80-83; Cheetham, G. M. T., and Steitz, T. A., Science 286 (1999) 2305-2309). The structure of the elongation complex solved at 2.9 A resolution showed the rearrangement of the N-terminal region (Tahirov, T. H., et al., Nature 420 (2002) 43-50). The structural studies showed that the conformation of the N-terminal domain changes between the initiation and elongation phases. Recently, the structure of transcribing T7 in transition from initiation to elongation phase was described (Durniak, K. J., et al., Science 322 (2008) 553-557).

The cloning and the expression of the gene encoding T7 has been described (Studier et al., U.S. Pat. No. 4,952,496). T7 has been studied intensively by mutagenesis to explore the conformational changes during transcription (Ma, K., et. al., Proc. Nat. Acad. Sci. 102 (2005) 17612-17617), to facilitate promoter clearance (Guillerez, J., et al., Proc. Natl. Acad. Sci. 102 (2005) 5958-5963) or to study the abortive cycling phenomenon (He, B., et al., J. Mol. Biol. 265 (1997) 275-288). Bonner, G., et al., J. Biol. Chem. 269 (1994) 25120-25128 described a set of active site mutants with altered elongation rates.

Due to the promoter specificity and high RNA polymerase enzymatic activity, T7 is useful for a variety of applications in molecular biology. In the field of recombinant protein expression T7 is used for the high-level expression of recombinant genes in E. coli (Studier, F. W., and Moffat, B. A., J. Mol. Biol. 189 (1986) 113-130). The synthesis of defined oligoribonucleotides was described by Milligan, J. F., et al., Nucl. Aids Res. 15 (1987) 8783-8798.

In addition, T7 is used in nucleic acid amplification methods for diagnostic purposes. A first example for such use is a technique known as “Nucleic Acid Sequence Based Amplification” (NASBA). This process comprises the steps of (a) adding a RNA template to a reaction mixture, wherein a first primer anneals to a complementary site at the 3′ end of the template; (b) reverse transcribing a DNA strand complementary to the RNA template, wherein a RNA/DNA heteroduplex is formed; (c) degrading the RNA strand of the heteroduplex by way of RNaseH activity; (d) annealing a second primer to the 5′ end of the DNA strand; (e) repeatedly synthesizing a complementary RNA strand with T7 RNA polymerase, wherein the synthesized RNA strand can serve again as a template in step (a). The NASBA technique has been used to develop rapid diagnostic tests for several pathogenic viruses, particularly those with single-stranded RNA genomes.

A further example for a diagnostic isothermal amplification method is “Transcription mediated amplification” (TMA) known to be one of the most sensitive detection assays for hepatitis C virus RNA in patient serum. For amplification of target RNA, two enzymes are used which are reverse transcriptase (RT) and T7 RNA polymerase. Complementary DNA (cDNA) of sample RNA is generated by RT with RNAse H activity and a primer containing a T7-promoter at the 5′-end. The RNA resulting of the RNA-DNA duplex is degradated by RNAse H activity of the RT. Another primer then binds to the cDNA already containing the T7-promotor sequence from the first primer and a double-stranded DNA is synthesized by the DNA polymerase activity of the RT. The T7 RNA polymerase recognizes the T7-promoter sequence within the double-stranded DNA molecule and synthesizes numerous RNA antisense transcripts. Each of the newly produced RNA amplicons re-enters the TMA process and serves as a template for a new round of RT to double-stranded DNA including the T7-promotor and transcription of antisense amplicons. The circulation of antisense transcripts into the amplification process results in exponential amplification of target RNA.

For NASBA, TMA and related methods as well as for other applications it would be advantageous if the reaction temperature could be elevated to improve the reaction kinetics. E.g., higher reaction temperatures of isothermal amplification could allow the amplification of RNA having secondary structures. It has also been shown with the polymerase chain reaction (PCR) technology that high annealing temperatures allow the specific hybridization of a primer to its target resulting in a highly specific amplification. With the same advantage, more thermostable enzymes could in principle also be applied isothermal amplifications.

Therefore, there is a need of a T7 RNA polymerase with improved stability and activity at higher reaction temperatures.

The stability of T7 RNA polymerase has been studied extensively. Thermal and urea-induced unfolding of was studied by Protasevich et al. using calorimetry, circular dichronism and fluorescence (Protasevich, I. I., et al., FEBS Lett 349 (1994) 429-432). Under the conditions used the enzyme unfolded at 48.3° C. Thermal unfolding was also studied by Griko et al. using calorimetric methods (Griko, Y., et al., Prot. Sci. 10 (2001) 845-853). A smaller 22 kDa N-terminal part of the enzyme was shown to increase the thermostability of the C-terminal 77 kDa domain.

By introducing point mutations in the sequence of the wild-type enzyme T7 variants were generated in which the stability of T7 RNA polymerase was enhanced. The patents U.S. Pat. No. 6,524,828 and EP 1 261 696 describe four distinct amino acid exchanges in the T7 RNA polymerase polypeptide (Ser430Pro, Ser633Pro, Phe849Ile and Phe880Tyr) which stabilize the enzyme. Combinations of two or more of these mutations in a modified T7 polypeptide result in even more stable enzyme variants.

The aim of the present invention was to extend the collection of stabilizing mutations by creating novel mutations in T7 RNA polymerase which lead to improved stability. It is further desired to combine several of these mutations in a single T7 variant (double-, triple-, quadruple-, multiple-mutant), provided the combined mutations lead to an even increased stability, that is to say thermostability. According to the invention, new mutations are found giving rise to T7 variants which exhibit high stability in thermal unfolding assays.

SUMMARY OF THE INVENTION

A first aspect of the invention is a variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, wherein the variant comprises a polypeptide of the wild-type reference in which at least one amino acid and up to four amino acids at different positions is/are substituted, wherein a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Ser633, Val650, Thr654, Ala702, and Val795, numbered from the N-terminus of the wild-type reference, and wherein the different amino acid is selected from the group consisting of Leu, Ile and Phe when the different amino acid substitutes for Val426 (Val426Leu, Val426Ile, Val426Phe), Val and Met when the different amino acid substitutes for Ser633 (Ser633Val, Ser633Met), Leu when the different amino acid substitutes for Val650 (Val650Leu), Leu when the different amino acid substitutes for Thr654 (Thr654Leu), Val when the different amino acid substitutes for Ala702 (Ala702Val), Ile when the different amino acid substitutes for Val795 (Val795Ile).

In a first embodiment, a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Val650, Ala702, and Val795. In a preferred embodiment, four amino acids at different positions are substituted, and the different amino acids are Val426Leu, Val650Leu, Ala702Val, and Val795Ile. In yet a further preferred embodiment, a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Ala702, and Val795, and wherein up to three amino acids at different positions is/are substituted. In yet a further preferred embodiment, two or three amino acids at different positions are substituted, and the different amino acids are selected from the group consisting of Val426Leu, Ala702Val, and Val795Ile. In yet a further preferred embodiment, three amino acids at different positions are substituted and the different amino acids are Val426Leu, Ala702Val, and Val795Ile.

A second aspect of the invention is a method to produce a variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, said method comprising the steps of (a) selecting an amino acid from the group consisting of Val426, Ser633, Val650, Thr654, Ala702, and Val795, numbered from the N-terminus of the wild-type reference; (b) substituting a selected amino acid with a different amino acid to form a T7 variant, wherein the different amino acid is selected from the group consisting of Leu, Ile and Phe when the different amino acid substitutes for Val426 (Val426Leu, Val426Ile, Val426Phe), Val and Met when the different amino acid substitutes for Ser633 (Ser633Val, Ser633Met), Leu when the different amino acid substitutes for Val650 (Val650Leu), Leu when the different amino acid substitutes for Thr654 (Thr654Leu), Val when the different amino acid substitutes for Ala702 (Ala702Val), Ile when the different amino acid substitutes for Val795 (Val795Ile), wherein of the wild-type reference at least one amino acid and up to four amino acids at different positions is/are substituted; (c) expressing a nucleic acid molecule encoding the T7 variant with the substituted amino acids of step (b) in a transformed host organism, and isolating the expressed T7 variant from the host organism; thereby producing the T7 variant.

A third aspect of the invention is a method to produce a nucleic acid molecule encoding a variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, said method comprising the steps of (a) reverse transcribing an amino acid sequence of a polypeptide according to the invention or an amino acid sequence of a polypeptide obtainable by the method according to the invention, thereby obtaining a nucleic acid sequence; followed by (b) synthesizing a nucleic acid molecule with the nucleic acid sequence obtained after performing step (a); thereby producing the nucleic acid molecule encoding the T7 variant.

A preferred embodiment of the invention is a nucleic acid molecule with a sequence encoding a variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, said nucleic acid being obtainable by the method of the invention. Yet, a further preferred embodiment of the invention is a nucleic acid molecule, wherein said nucleic acid is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, and SEQ ID NO: 47.

A fourth aspect of the invention is an expression vector comprising a nucleic acid molecule according to the invention, wherein said nucleic acid molecule is functionally linked to one or more sequences capable of controlling transcription and/or translation.

A fifth aspect of the invention is a host organism capable of recombinant expression of a polypeptide, wherein said host organism is transformed with an expression vector according to the invention.

A sixth aspect of the invention is a method to synthesize a RNA molecule, comprising the steps of (a) providing a template DNA molecule comprising a T7 promoter, said T7 promoter being functionally linked to a target nucleotide sequence to be transcribed; (b) contacting the template DNA of step (a) with a variant polypeptide of T7 RNA polymerase (T7 variant) according to the invention or a T7 variant obtainable by the method of the inevtion; followed by (c) incubating the template DNA and the T7 variant in the presence of ribonucleoside triphosphates; thereby synthesizing the RNA molecule.

A seventh aspect of the invention is a composition comprising a template DNA molecule with a T7 promoter functionally coupled to a target nucleotide sequence to be transcribed, ribonucleoside triphosphates, and a variant polypeptide of T7 RNA polymerase (T7 variant) according to the invention or a T7 variant obtainable by the method according to the invention.

An eighth aspect of the invention is a kit comprising, in separate containers, a variant polypeptide of T7 RNA polymerase (T7 variant) according to the invention or a T7 variant obtainable by the method according to the invention and a buffer with one or more ribonucleoside triphosphates.

DETAILED DESCRIPTION OF THE INVENTION

The present invention aims at providing the skilled person with novel variants of T7 polymerase which are characterized by (i) a DNA-dependent RNA polymerase enzymatic activity, (ii) an enhanced thermostability compared to the wild-type T7 RNA polymerase polypeptide (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference. Such a “variant” is an allelic form of the wild-type T7 protein, wherein said variant is generated by way of amino acid substitution.

Certain terms are used with particular meaning or are defined for the first time in this description of the present invention. For the purposes of the invention, the terms used are defined by their art-accepted definitions, when such exist, except that when those definitions conflict or partially conflict with the definitions set forth below. In the event of a conflict in definition, the meaning of a term is first defined by any of the definitions set forth in this document.

The term “comprising” is used in the description of the invention and in the claims to mean “including, but not necessarily limited to”.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “a compound” means one compound or more than one compound.

If not stated otherwise, it is understood that the term “about” in combination with a numerical value n (“about n”) indicates a value x in the interval given by the numerical value ±5% of the value, i.e., n−0.05*n×n+0.05*n. In case the term “about” in combination with a numerical value n describes a preferred embodiment of the invention, the value of n is most preferred, if not indicated otherwise.

A nucleotide sequence “encodes” a peptide or polypeptide when at least a portion of the nucleic acid, or its complement, can be directly translated to provide the amino acid sequence of the peptide or protein, or when the isolated nucleic acid can be used, alone or as part of an expression vector, to express the peptide or protein in vitro, in a prokaryotic host cell, or in a eukaryotic host cell.

Where a nucleotide sequence is single-stranded, it is to be understood that the complementary sequence of that nucleotide sequence is also included within the scope of the present invention.

The coding portion of a nucleotide sequence encoding a peptide or a polypeptide begins with a start codon encoding Methionine which thus becomes the N-terminal amino acid of the primary translation product. As part of post-translational processes, the N-terminal Methionine is frequently cleaved off, e.g., by a Methionine aminopeptidase which is a ubiquituous enzyme. In such a case, the primary translation product may give rise to a mixture comprising members without N-terminal Methionine and members retaining this amino acid as N-terminus. It is also possible that the form of the enzyme without N-terminal Methionine is the only one which can be isolated. However, the amino acid sequences of the wild-type T7 polymerase and the T7 variants according to the invention are described in the sequence listing including N-terminal Methionine. But the present invention also encompasses the said T7 variants which do not include N-terminal Methionine.

For purposes of shorthand designation of T7 polymerase variants described herein, it is noted that for each mutation a number refers to the amino acid residue/position along the reference amino acid sequence of the wild-type T7 polymerase protein given in SEQ ID NO: 2. Amino acid identification uses the three-letter abbreviations as well as the single-letter alphabet of amino acids, i.e., Asp D Aspartic acid, Ile I Isoleucine, Thr T Threonine, Leu L Leucine, Ser S Serine, Tyr Y Tyrosine, Glu E Glutamic acid, Phe F Phenylalanine, Pro P Proline, His H Histidine, Gly G Glycine, Lys K Lysine, Ala A Alanine, Arg R Arginine, Cys C Cysteine, Trp W Tryptophan, Val V Valine, Gln Q Glutamine, Met M Methionine, Asn N Asparagine. An amino acid at a particular position in an amino acid sequence is given by its three-letter abbreviation and a number. Accordingly, any of “Leu705” and “L705” denote the leucine residue at amino acid position 705 in SEQ ID NO: 2. In any T7 mutant and/or T7 variant disclosed herein, a substitution by a different amino acid is given as the three-letter abbreviation added after the number indicating the position. E.g., “Leu705Ile” (=[Leu705Ile]) or “L705I” (=[L705I]) denote the substitution of Leu at position 705 in SEQ ID NO: 2 by Ile (see #16 of Table 3). A Leu705Ile (=L705I) substitution results in an amino acid sequence as given in SEQ ID NO: 28, encoded by the nucleotide sequence of SEQ ID NO: 27. Preferred amino acid substitutions are disclosed in Table 1 further below (see Example 1). Particularly preferred variants according to the invention are characterized by a plurality (preferred 2 to 4) of amino acid substitutions. Examples therefor can be found in Table 4, for example—but not limited to—#24 [Val426Leu, Val795Ile] or #25 [Val426Leu, Ala702Val, Val7951Ile].

The term “polypeptide” or “protein” denotes a polymer composed of a plurality of amino acid monomers joined by peptide bonds. Preferably, the polymer comprises 50 or more monomers. A preferred polypeptide or protein according to the invention is a T7 variant. A “peptide bond” is a covalent bond between a first amino acid and a second amino acid in which the α-amino group of the first amino acid is bonded to the α-carboxyl group of the second amino acid.

The T7 variants of the invention also comprise fusion proteins with an affinity tag such as, but not limited to, a Histidine tag (His-tag). Well known to the skilled artisan, a His-tag is an amino acid sequence containing several, preferably 3 to 7, more preferred 6 consecutive Histidines (SEQ ID NO: 53). In a His-tag sequence the Histidines represent the essential portion. But facultatively there are few additional amino acids comprised in the His-tag. For example, a N-terminal T7 sequence including a His-tag can comprise the sequence N-Met His His His His His His Gly Ser- (residues 1-9 of SEQ ID NO: 52). To this end see SEQ ID NO: 52 comprising the foregoing amino acid sequence. In the present exemplary His-tag the amino acids Gly and Ser form a linker to the N-terminus of the T7 variant. The linker amino acids are part of the His-tag and typically arise as a cloning artifact of the nucleotide sequence encoding the His-tag (e.g., SEQ ID NO: 51). Preferably, the linker sequence in the His-tag comprises 1 to 5 amino acids.

According to the invention, the N-terminal Methionine of a T7 variant can be replaced by a His-tag. Alternatively, the N-terminal sequence of the T7 variant according to the invention can be extended by the His-tag. In such a case, the N-terminus of the primary translation product of the T7 variant comprises a N-terminal Methionine followed by the His-tag, followed by the Methionine encoded by the start codon of the original T7 encoding nucleotide sequence.

Purification of a His-tagged T7 wild-type or variant polypeptide is efficiently performed by immobilized metal affinity chromatography. This method is a widely employed method to purify recombinant proteins containing a short affinity-tag consisting of Histidine residues (His-tag). Immobilized metal-affinity chromatography (described by Porath, J., et al., Nature 258 (1975) 598-599) is based on the interaction between a transition metal ion (Co2+, Ni2+, Cu2+, Zn2+) immobilized on a particulate metal chelating affinity matrix and specific amino acid side chains. Histidine is the amino acid that exhibits the strongest interaction with immobilized metal ion matrices, as electron donor groups on the Histidine imidazole ring readily form coordination bonds with the immobilized transition metal.

A “vector” is defined as a DNA which can comprise, i.e., carry, and maintain a DNA fragment according to the invention, including, for example, phages and plasmids. These terms are understood by those of skill in the art of genetic engineering. The term “expression cassette” denotes a nucleotide sequence encoding a pre-protein, operably linked to a promoter and a terminator. As for vectors containing an expression cassette, the terms “vector” and “expression vector” are used as synonyms.

The term “oligonucleotide” is used for a nucleic acid molecule, DNA (or RNA), with less than 100 nucleotides in length. Preferably, an oligonucleotide is about 75, about 50 or less nucleotides in length

“Transformation” means introducing DNA into an organism, i.e., a host organism, so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration.

The term “expression” and the verb “to express” denote transcription of DNA sequences and/or the translation of the transcribed mRNA in a host organism resulting in a pre-protein, i.e., not including post-translational processes.

A “promoter” is a regulatory nucleotide sequence that stimulates transcription. These terms are understood by those of skill in the art of genetic engineering. Like a promoter, a “promoter element” stimulates transcription but constitutes a sub-fragment of a larger promoter sequence.

The term “operably linked” refers to the association of two or more nucleic acid fragments on a single vector so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence, i.e., a nucleotide sequence encoding a protein or a pre-protein, when it is capable of affecting the expression of that coding sequence, i.e., that the coding sequence is under the transcriptional control of the promoter.

According to the invention, a first embodiment is a variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, wherein the variant comprises a polypeptide of the wild-type reference in which at least one amino acid and up to four amino acids at different positions is/are substituted, wherein a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Ser633, Val650, Thr654, Ala702, and Val795, numbered from the N-terminus of the wild-type reference, and wherein the different amino acid is selected from the group consisting of

    • Leu, Ile and Phe when the different amino acid substitutes for Val426 (Val426Leu, Val426Ile, Val426Phe),
    • Val and Met when the different amino acid substitutes for Ser633 (Ser633Val, Ser633Met),
    • Leu when the different amino acid substitutes for Val650 (Val650Leu),
    • Leu when the different amino acid substitutes for Thr654 (Thr654Leu),
    • Val when the different amino acid substitutes for Ala702 (Ala702Val),
    • Ile when the different amino acid substitutes for Val795 (Val795Ile).

The experimental work underlying the above selections basically followed a rational approach to introduce at selected positions predetermined amino acid substitutions in the T7 polypeptide. Among a large number of mutations tested, several unexpectedly inhibited T7 polymerase activity, others—against the prediction—did not noticeably enhance thermostability; only a few mutations in fact showed the desired effects.

Since the development of site-directed mutagenesis protocols, modification of enzyme-encoding nucleotide sequences has become a powerful method in the field of protein engineering (Winter, G., et al., Nature 299 (1982) 756-758). The knowledge of the structure of an enzyme—combined with detailed biochemical data concerning the principles underlying its function and stability—offers the opportunity to rationally design enzymes with improved properties. Examples for improvements are, e.g., enhanced specificity, altered substrate spectrum, and thermostability. The latter kind of improvements is pursued in the present case.

Fersht & Serrano discussed general principles of protein stability derived from protein engineering experiments (Fersht, A. R., and Serrano, L., Curr. Opin. Struct. Biol. 3 (1993) 75-83). The specific interactions between amino acids in a protein and the effect on stability were described. With regards to the stabilization of a protein an improvement was exemplified by “filling” hydrophobic cavities in the inner core of a protein with hydrophobic amino acid residues. It was shown that by these means the overall hydrophobic interaction in the protein core was increased and that an increase of thermostability of the target protein was achieved. Further developments in the field of stabilization of protein structures were reviewed by Lee, B., and Vasmatzis, G., Current Opinion Biotechn. 8 (1997) 423-428.

With the aim of applying this knowledge to the development of the desired T7 variants, high resolution x-ray structures of T7 RNA polymerase deposited in data banks were carefully inspected. Candidate sites in the protein structures were identified and sites were selected where certain mutations could improve the stability of the enzyme. The designed variants were synthesized, cloned, expressed and purified. The stability of the enzyme variants was examined and compared with the stability of the wild-type enzyme. Table 3 in Example 1 summarizes the mutations considered in the experimental work underlying the present invention.

To determine of the stability of wild-type T7 polymerase and T7 variants two parameters were examined: (i) the half-life time under a predetermined temperature regime, and (ii) the melting temperature (Tm).

In yet more detail, the present invention embodies the following items.

1. A variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference,

    • wherein the variant comprises a polypeptide of the wild-type reference in which at least one amino acid and up to four amino acids at different positions is/are substituted,
    • wherein a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Ser633, Val650, Thr654, Ala702, and Val795, numbered from the N-terminus of the wild-type reference, and
    • wherein the different amino acid is selected from the group consisting of
      • Leu, Ile and Phe when the different amino acid substitutes for Val426 (Val426Leu, Val426Ile, Val426Phe),
      • Val and Met when the different amino acid substitutes for Ser633 (Ser633Val, Ser633Met),
      • Leu when the different amino acid substitutes for Val650 (Val650Leu),
      • Leu when the different amino acid substitutes for Thr654 (Thr654Leu),
      • Val when the different amino acid substitutes for Ala702 (Ala702Val),
      • Ile when the different amino acid substitutes for Val795 (Val795Ile).

2. The T7 variant according to item 1, wherein a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Val650, Ala702, and Val795.

3. The T7 variant according to item 2, wherein four amino acids at different positions are substituted, and the different amino acids are Val426Leu, Val650Leu, Ala702Val, and Val795Ile.

4. The T7 variant according to item 1, wherein a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Ala702, and Val795, and wherein up to three amino acids at different positions is/are substituted.

5. The T7 variant according to item 4, wherein two or three amino acids at different positions are substituted, and the different amino acids are selected from the group consisting of Val426Leu, Ala702Val, and Val795Ile.

6. The T7 variant according to item 4, wherein three amino acids at different positions are substituted and the different amino acids are Val426Leu, Ala702Val, and Val1795Ile.

7. The T7 variant according to any of the items 1 to 6, additionally comprising a tag (affinity tag) capable of specifically binding to an affinity chromatography matrix.

8. The T7 variant according to any of the items 1 to 7, wherein the affinity tag is a Histidine tag.

9. The T7 variant according to item 8, wherein the Histidine tag is a C-terminal tag.

10. The T7 variant according to item 8, wherein the Histidine tag is a N-terminal tag.

11. The T7 variant according to item 10, additionally comprising a linker sequence linking the Histidine tag with the amino acid corresponding to Met1 or Asn2 of SEQ ID NO: 2.

12. The T7 variant according to item 11, wherein the linker sequence consists of between 1 and 4 amino acids.

13. The T7 variant according to item 12, wherein the linker sequence consists of between 1 and 2 amino acids.

14. The T7 variant according to any of the items 1 to 13, wherein at 50° C. the half-life time of the variant is between 12 min and about 320 min, and particularly between 12 min and about 312 min; preferably, the T7 variant comprises (i) a single amino acid substitution selected from the group consisting of [Val426Leu], [Val426Ile], [Val426Phe], [Ser633Met], [Val650Leu], [Thr654Leu], [Ala702Val], and [Val795Ile], or (ii) a double amino acid substitution selected from the group consisting of [Ala702Val, Val1795Ile], [Val426Leu, Ala702Val], and [Val426Leu, Val795Ile], or (iii) the triple amino acid substitution [Val426Leu, Ala702Val, Val795Ile], or (iv) the quadruple amino acid substitution [Val426Leu, Val650Leu, Ala702Val, Val795Ile].

15. The T7 variant according to item 14, wherein the half-life time is between about 20 min and about 320 min, and particularly between 20 min and about 312 min.

16. The T7 variant according to item 14, wherein the half-life time is between about 30 min and about 320 min, and particularly between about 30 min and about 312 min.

17. The T7 variant according to item 14, wherein the half-life time is between about 40 min and about 320 min, and particularly between about 40 min and about 312 min.

18. The T7 variant according to item 14, wherein the half-life time is between about 60 min and about 320 min, and particularly between about 60 min and about 312 min.

19. The T7 variant according to item 14, wherein the half-life time is about 320 min.

20. The T7 variant according to item 14, wherein the half-life time is about 312 min.

21. A method to produce a variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, said method comprising the steps of

    • (a) selecting an amino acid from the group consisting of Val426, Ser633, Val650, Thr654, Ala702, and Val795, numbered from the N-terminus of the wild-type reference;
    • (b) substituting a selected amino acid with a different amino acid to form a T7 variant, wherein the different amino acid is selected from the group consisting of
      • Leu, Ile and Phe when the different amino acid substitutes for Val426 (Val126Leu, Val426Ile ,Val426Phe),
      • Val and Met when the different amino acid substitutes for Ser633 (Ser633Val, Ser633Met),
      • Leu when the different amino acid substitutes for Val650 (Val650Leu),
      • Leu when the different amino acid substitutes for Thr654 (Thr654Leu),
      • Val when the different amino acid substitutes for Ala702 (Ala702Val),
      • Ile when the different amino acid substitutes for Val795 (Val795Ile), wherein at least one amino acid of the wild-type reference and up to four amino acids at different positions is/are substituted;
    • (c) expressing a nucleic acid molecule with a nucleotide sequence encoding the T7 variant with the substituted amino acids of step (b) in an expression system transformed host organism, and isolating the expressed T7 variant from the expression system host organism;
      thereby producing the T7 variant.

22. The method of item 21, wherein the expression system is selected from the group consisting of a transformed host organism and a cell-free expression system.

23. The method according to any of the items 21 and 22, wherein in step (c) the nucleic acid molecule encodes a T7 variant according to any of the items 1 to 20.

24. A method to produce a nucleic acid molecule with a nucleotide sequence encoding a variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, said method comprising the steps of

    • (a) reverse transcribing an amino acid sequence of a polypeptide according to any of the items 1 to 20 or an amino acid sequence of a polypeptide obtainable by the method according to any of the items 21 to 23, thereby obtaining a nucleic acid sequence; followed by
    • (b) synthesizing a nucleic acid molecule with the nucleic acid sequence obtained after performing step (a);
    • thereby producing the nucleic acid molecule encoding the T7 variant.

25. A nucleic acid molecule with a nucleotide sequence encoding a variant polypeptide of T7 RNA polymerase (T7 variant), said T7 variant being characterized by (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to the 883-amino acid T7 RNA polymerase polypeptide of SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, said nucleic acid being obtainable by the method of item 24.

26. The nucleic acid molecule according to item 25, wherein the nucleotide sequence of said nucleic acid comprises a sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, and SEQ ID NO: 47.

27. An expression vector comprising a nucleic acid molecule according to any of the items 25 and 26, wherein said nucleic acid molecule is functionally linked to one or more nucleotide sequences capable of controlling transcription and/or translation.

28. A host organism capable of recombinant expression of a polypeptide, wherein said host organism is transformed with an expression vector according to item 27.

29. A method to synthesize a RNA molecule, comprising the steps of

    • (a) providing a template DNA molecule comprising a T7 promoter, said T7 promoter being functionally linked to a target nucleotide sequence to be transcribed;
    • (b) contacting the template DNA of step (a) with a variant polypeptide of T7 RNA polymerase (T7 variant) according to any of the items 1 to 20 or a T7 variant obtainable by the method according to any of the items 21 to 23; followed by
    • (c) incubating the template DNA and the T7 variant in the presence of ribonucleoside triphosphates;
    • thereby synthesizing the RNA molecule.

30. The method according to item 29, wherein step (c) is performed at a temperature from 4° C. to 55° C., more preferred at a temperature from 18° C. to 50° C., and even more preferred at a temperature from 37° C. to 50° C.

31. A composition comprising (i) a template DNA molecule, the template DNA molecule comprising a

T7 promoter which is functionally coupled to a target nucleotide sequence to be transcribed, (ii) ribonucleoside triphosphates, (iii) an aqueous buffer, and (iv) a variant polypeptide of T7 RNA polymerase (T7 variant) according to any of the items 1 to 20 or a T7 variant obtainable by the method according to any of the items 21 to 23.

32. Use of a composition according to item 31 in a method according to any of the items 29 and 30.

33. A kit comprising, in separate containers, a variant polypeptide of T7 RNA polymerase (T7 variant) according to any of the items 1 to 20 or a T7 variant obtainable by the method according to any of the items 21 to 23, and an aqueous buffer with one or more ribonucleoside triphosphates.

34. Use of a kit according to item 33 in a method according to any of the items 29 and 30.

The following examples and sequence listing are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

DESCRIPTION OF THE SEQUENCE LISTING

SEQ ID NO: 1 DNA (=nucleic acid; here and in the following SEQ ID NO items to be read as DNA, if not indicated otherwise) sequence encoding wild-type T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #1 in Table 3.

SEQ ID NO: 2 Wild-type T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #1 in Table 3.

SEQ ID NO: 3 DNA sequence encoding the A319S variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #2 in Table 3.

SEQ ID NO: 4 A319S variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #2 in Table 3.

SEQ ID NO: 5 DNA sequence encoding the A319V variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #3 in Table 3.

SEQ ID NO: 6 A319V variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #3 in Table 3.

SEQ ID NO: 7 DNA sequence encoding the A319P variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #4 in Table 3.

SEQ ID NO: 8 A319P variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #4 in Table 3.

SEQ ID NO: 9 DNA sequence encoding the V426L variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #5 in Table 3.

SEQ ID NO: 10 V426L variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #5 in Table 3.

SEQ ID NO: 11 DNA sequence encoding the V4261 variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #6 in Table 3.

SEQ ID NO: 12 V4261 variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #6 in Table 3.

SEQ ID NO: 13 DNA sequence encoding the V426F variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #7 in Table 3.

SEQ ID NO: 14 V426F variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #7 in Table 3.

SEQ ID NO: 15 DNA sequence encoding the S633V variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #10 in Table 3.

SEQ ID NO: 16 S633V variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #10 in Table 3.

SEQ ID NO: 17 DNA sequence encoding the S633L variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #11 in Table 3.

SEQ ID NO: 18 S633L variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #11 in Table 3.

SEQ ID NO: 19 DNA sequence encoding the S633M variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #12 in Table 3.

SEQ ID NO: 20 S633M variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #12 in Table 3.

SEQ ID NO: 21 DNA sequence encoding the V650L variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #13 in Table 3.

SEQ ID NO: 22 V650L variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #13 in Table 3.

SEQ ID NO: 23 DNA sequence encoding the T654L variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #14 in Table 3.

SEQ ID NO: 24 T654L variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #14 in Table 3.

SEQ ID NO: 25 DNA sequence encoding the A702V variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #15 in Table 3.

SEQ ID NO: 26 A702V variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #15 in Table 3.

SEQ ID NO: 27 DNA sequence encoding the L7051 variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #16 in Table 3.

SEQ ID NO: 28 L7051 variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #16 in Table 3.

SEQ ID NO: 29 DNA sequence encoding the V7951 variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #18 in Table 3.

SEQ ID NO: 30 V7951 variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #18 in Table 3.

SEQ ID NO: 31 DNA sequence encoding the L809F variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #19 in Table 3.

SEQ ID NO: 32 L809F variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #19 in Table 3.

SEQ ID NO: 33 DNA sequence encoding the F814W variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #20 in Table 3.

SEQ ID NO: 34 F814W variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #20 in Table 3.

SEQ ID NO: 35 DNA sequence encoding the M861W variant of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #21 in Table 3.

SEQ ID NO: 36 M861W variant of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #21 in Table 3.

SEQ ID NO: 37 DNA sequence encoding the A702V, V795I variant (double mutant) of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #22 in Table 3.

SEQ ID NO: 38 A702V, V795I variant (double mutant) of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #22 in Table 3.

SEQ ID NO: 39 DNA sequence encoding the V426L, A702V variant (double mutant) of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #23 in Table 3.

SEQ ID NO: 40 V426L, A702V variant (double mutant) of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #23 in Table 3.

SEQ ID NO: 41 DNA sequence encoding the V426L, V795I variant (double mutant) of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #24 in Table 3.

SEQ ID NO: 42 V426L, V795I variant (double mutant) of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #24 in Table 3.

SEQ ID NO: 43 DNA sequence encoding the V426L, A702V, V795I variant (triple mutant) of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #25 in Table 3.

SEQ ID NO: 44 V426L, A702V, V795I variant (triple mutant) of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #25 in Table 3.

SEQ ID NO: 45 DNA sequence encoding the V426L, S633M, A702V, V795I variant (quadruple mutant) of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #26 in Table 3.

SEQ ID NO: 46 V426L, S633M, A702V, V795I variant (quadruple mutant) of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #26 in Table 3.

SEQ ID NO: 47 DNA sequence encoding the V426L, V650L, A702V, V795I variant (quadruple mutant) of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #27 in Table 3.

SEQ ID NO: 48 V426L, V650L, A702V, V795I variant (quadruple mutant) of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #27 in Table 3.

SEQ ID NO: 49 DNA sequence encoding the V426L, S633M, V650L, A702V, V795I variant (quintuple mutant) of T7 DNA-dependent RNA polymerase, including start codon encoding N-terminal Methionine; corresponding to #28 in Table 3.

SEQ ID NO: 50 V426L, S633M, V650L, A702V, V795I variant (quintuple mutant) of T7 DNA-dependent RNA polymerase, amino acid sequence including N-terminal Methionine; corresponding to #28 in Table 3.

SEQ ID NO: 51 DNA sequence encoding N-terminal Histidine tag (His6) (SEQ ID NO: 54) with linker sequence, fused to the first two N-terminal amino acids of T7 (Met and Asn).

SEQ ID NO: 52 Amino acid sequence of N-terminal Histidine (His6) tag (SEQ ID NO: 54) with linker sequence, fused to the first two N-terminal amino acids of T7 (Met and Asn).

Example 1: Design of Amino Acid Exchange Mutations in the T7 Polypeptide

X-ray structures of T7 RNA polymerase deposited in the Protein Data Bank (codes: lcez [referring to Cheetham, G. M. T., et al., Nature 399 (1999) 80-83], and 1s77 [referring to Yin, Y. W., and Steitz, T. A., Cell 116 (2004) 393-404]) were inspected to identify candidate sites for the introduction of mutations to increase the stability of the protein.

Selected positions of the T7 wild-type amino acid sequence (according to SEQ ID NO: 2) are shown in Table 1 which also provides amino acid substitution mutations expected to increase the stability of the T7 polymerase protein. The underlying rationale of the design of the mutations is also indicated.

Most of the substituting amino acids were selected either to fill hydrophobic cavities in the core or to stabilize loops located at the surface of the enzyme.

TABLE 1 Amino acid mutations of T7 RNA polymerase: Design of an enzyme with increased thermostability Amino acid, WT Position Mutation Rationale Ala 319 Ser, Val, Pro Fill cavity in protein core Val 426 Leu, Ile, Phe, Trp Fill cavity in protein core Val 629 Pro Stabilize loop Ser 633 Val, Leu, Met Stabilize loop Val 650 Leu Stabilize loop Thr 654 Leu Stabilize loop Ala 702 Val Fill cavity in protein core Leu 705 Ile Fill cavity in protein core Leu 791 Phe Fill cavity in protein core Val 795 Ile Fill cavity in protein core Leu 809 Phe Fill cavity in protein core Phe 814 Trp Fill cavity in protein core Met 861 Trp Fill cavity in protein core

In order to provide a coding sequence for any of the T7 mutants shown, the nucleotide sequence of SEQ ID NO: 1 encoding the T7 wild type reference polypeptide was used as a basis. The nucleotide codons corresponding to the amino acid residues at the positions indicated in Table 1 were mutated, in order to encode the changed amino acid at the respective position. Mutations were preferably designed in accordance with the codon usage bias of E. coli class II genes (Hénaut, A., and Danchin, A., Analysis and Predictions from Escherichia coli sequences. Escherichia coli and Salmonella, Vol. 2, Ch. 114 (1996) 2047-2066, Neidhardt F C ed., ASM press, Washington, D.C.), as given in Table 2.

TABLE 2 Codon usage in E. coli Amino Class Amino Class acid Codon I II III acid Codon I II III Phe T T T 55.09 29.08 67.14 Leu C T T 9.7 5.56 19 T T C 44.91 70.92 32.86 C T C 10.4 8.03 9.04 Leu T T A 10.99 3.44 20.09 C T A 3.09 0.83 6.81 T T G 13.02 5.47 15.05 C T G 52.79 76.67 29.99 Ser T C T 13.26 32.41 19.63 Pro C C T 13.71 11.23 28.3 T C C 15.02 26.56 11.34 C C C 11.19 1.63 16.26 T C A 10.83 4.79 22.09 C C A 18.63 15.25 31.5 T C G 16.88 7.39 10.6 C C G 56.47 71.89 23.94 Tyr T A T 54.42 35.23 69.6 His C A T 56.8 29.77 61.69 T A C 45.58 64.77 30.4 C A C 43.2 70.23 38.31 Stop T A A Gln C A A 33.4 18.65 37.06 T A G C A G 66.6 81.35 62.94 Cys T G T 40.9 38.85 55.71 Arg C G T 38.99 64.25 26.05 T G C 59.1 61.15 44.29 C G C 42.23 32.97 21.94 Stop T G A C G A 5.52 1.07 12.8 Trp T G G 100 100 100 C G G 8.97 0.8 13.62 Ile A T T 51.2 33.49 47.57 Val G T T 23.74 39.77 34.33 A T C 44.37 65.94 26.65 G T C 22.48 13.45 18.95 A T A 4.43 0.57 25.78 G T A 14.86 19.97 21.78 Met A T G 100 100 100 G T G 38.92 26.81 24.94 Thr A C T 14.85 29.08 26.83 Ala G C T 14.52 27.54 22.86 A C C 46.83 53.6 24.45 G C C 27.62 16.14 23.67 A C A 10.52 4.67 27.93 G C A 19.63 24.01 31.27 A C G 27.81 12.65 20.8 G C G 38.23 32.3 22.19 Asn A A T 40.87 17.25 64.06 Asp G A T 62.83 46.05 70.47 A A C 59.13 82.75 35.94 G A C 37.17 53.95 29.53 Lys A A A 75.44 78.55 72.21 Glu G A A 68.33 75.35 66.25 A A G 24.56 21.45 27.79 G A G 31.67 24.65 33.75 Ser A G T 13.96 4.52 18.73 Gly G G T 32.91 50.84 31.79 A G C 30.04 24.33 17.61 G G C 43.17 42.83 24.51 Arg A G A 1.75 0.62 15.63 G G A 9.19 1.97 24.75 A G G 1.54 0.29 9.96 G G G 14.74 4.36 18.95

The genes which served as the basis for the data in Table 2 were clustered by using factorial correspondence analysis into three classes. Class I contains genes involved in most metabolic processes. Class II genes correspond to genes highly and continuously expressed during exponential growth. Class III genes are implicated in horizontal transfer of DNA. One can see that the distribution of codons in class III genes is more or less even, whereas it is extremely biased in class II genes (in particular, codons terminated in A are selected against).

The mutations on the codon level which were introduced in the T7 coding sequence are shown in Table 3.

TABLE 3 T7 polymerase and variants thereof # T7 enzyme/variant WT codon Mutated codon SEQ ID NO: 1 Wild-type — 1, 2 2 Ala319Ser GCG AGC 3, 4 3 Ala319Val GCG GTT 5, 6 4 Ala319Pro GCG CCG 7, 8 5 Val426Leu GTT CTG  9, 10 6 Val426Ile GTT ATC 11, 12 7 Val426Phe GTT TTC 13, 14 8 Val426Trp GTT TGG 9 Val629Pro GTG CCG 10 Ser633Val TCA GTT 15, 16 11 Ser633Leu TCA CTG 17, 18 12 Ser633Met TCA ATG 19, 20 13 Val650Leu GTG CTG 21, 22 14 Thr654Leu ACC CTG 23, 24 15 Ala702Val GCT GTT 25, 26 16 Leu705Ile CTG ATC 27, 28 17 Leu791Phe CTT TTC 18 Val795Ile GTA ATC 29, 30 19 Leu809Phe CTG TTC 31, 32 20 Phe814Trp TTC TGG 33, 34 21 Met861Trp ATG TGG 35, 36 22 Ala702Val GCT GTT 37, 38 Val795Ile GTA ATC 23 Val426Leu GTT CTG 39, 40 Ala702Val GCT GTT 24 Val426Leu GTT CTG 41, 42 Val795Ile GTA ATC 25 Val426Leu GTT CTG 43, 44 Ala702Val GCT GTT Val795Ile GTA ATC 26 Val426Leu GTT CTG 45, 46 Ser633Met TCA ATG Ala702Val GCT GTT Val795Ile GTA ATC 27 Val426Leu GTT CTG 47, 48 Val650Leu GTG CTG Ala702Val GCT GTT Val795Ile GTA ATC 28 Val426Leu GTT CTG 49, 50 Ser633Met TCA ATG Val650Leu GTG CTG Ala702Val GCT GTT Val795Ile GTA ATC

On the amino acid level, the T7 variants are shown in SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, and 50.

The nucleotide sequences encoding the mutated T7 polypeptides which were expressed in E. coli are shown in SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 49. The sequences are represented including the start codons for N-terminal Methionine but without any other additional artificial N-terminal structures such as His-tags.

Well-known to the art, a His-tag (in the literature also referred to as a polyHis-tag) is an amino acid motif in proteins that typically consists of at least six consecutive His residues (His6) (SEQ ID NO: 54). While the N-terminus of a T7 variant is preferred for the addition of the His-tag, the C-terminus of the polypeptide can serve as an alternative.

For clarification, a N-terminal His-tag can be located between the Methionine at the N-terminus of the respective variant T7 polypeptide and the subsequent amino acid according to the amino acid sequence of SEQ ID NO: 2, i.e., Asn. Alternatively, the His-tag can be appended to the N-terminal Methionine of the T7 variant. When appended at the C-terminus of the variant T7 polypeptide the His-tag forms the C-terminal amino acids.

The T7 variants were modified further such that each polypeptide contained a His-tag at its N-terminus to facilitate purification.

Apart from the Histidines the His-tag can additionally comprise further amino acids depending on the design of the nucleotide sequence encoding the His-tag. Thus, an oligonucleotide linker with restriction sites typically adds 1 to 5 further amino acids to the nucleotide fragment encoding the consecutive His residues in the His-tag.

The amino acid sequences of the T7 variants of Table 1 and the nucleic acid sequences encoding the T7 variants are shown in the sequence listing of this disclosure. No His-tags are shown as these may differ sequence-wise, depending on the particular cloning vector used. However, the differences concerning the number of Histidines and the linker sequence, according to the preferred embodiments, are not expected to have a technical impact on the T7 variants according to the invention.

Example 2: Cloning of Nucleic Acids Encoding Variants of T7 RNA Polymerase

All molecular biological procedures were performed according to standard methods (Sambrook J., Fritsch E. F., Maniatis T., (1989) Molecular cloning: A Laboratory Manual second Edition, B.27 Cold Spring Harbor Laboratory Press NY (USA)). Nucleotide sequences encoding the wild-type and the mutant T7 polypeptides were synthesized by a combinatorial synthesis strategy as described (van den Brulle, J., et al., Biotechniques 45(3) (2008) 340-343).

For expression of each of the T7 variants, the respective coding DNA sequence was cloned in appropriate expression vectors in such a way that the mutated T7 coding sequence is inserted in the right orientation under the control of an appropriate promoter, preferably an inducible promoter, particularly preferably the lac-, lacUV5-, tac- or T5 promoter. Preferred expression vectors are pUC plasmids with lac- or lacUV5 promoters or pKK plasmids. For clarification an exemplary coding sequence comprises a DNA encoding a polypeptide selected from any of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, and 49 which optionally include a further modification such as a His-tag.

The synthesized genes were cloned in plasmid pUC18. The recipient strain for transformations was E. coli XL-1 blue. Transformed clones were grown at 37° C. in LB media containing ampicillin (100 μg/ml). Plasmids were isolated and digested using EcoRI and HindIII. The resulting fragments were subjected to agarose gel electrophoresis and the respective band corresponding to the variant T7 polymerase coding sequence was extracted. The isolated fragments were ligated into the expression plasmid pKKT5 (derived from pKK177-3 [Kopetzki, E., et al., Mol. Gen. Genet. 216 (1989) 149-155] by exchanging the tac-promotors with the T5-promoter derived from the plasmid pDS [Bujard, H., et al., Methods Enzymol. 155 (1987) 416-433]) which was digested with EcoRI and HindIII.

Plasmids were transformed into E. coli UT5600 (harboring plasmid pUBS520). Clones were grown at 37° C. in LB media containing ampicillin (100 μg/ml) and kanamycin (50 μg/ml).

Example 3: Expression and Purification of Variant T7 Polymerase Polypeptides

Transformed E. coli expression strains obtained as described in Example 2 were cultivated at 37° C. in LB media containing ampicillin (100 μg/ml) and kanamycin (50 μg/ml). Induction of recombinant expression was performed at an optical density of 0.7 (measured at 578 nm) by adding IPTG in a final concentration of 1 mM. After 5 hours the cells were harvested by centrifugation and frozen at −20° C.

His-tagged wild-type T7 polymerase and T7 variants were purified separately to homogeneity using metal chelate affinity matrix chromatography. Typically, wet frozen cells (2.1 g) were suspended in 30 ml buffer A (50 mM Tris/HCl, pH 8.1 [pH adjusted at room temperature], 1 M NaCl). To the suspension 315 μl of a lysozyme solution (10 mg/ml) were added. After incubation at room temperature for 15 min, the cells were sonicated (6×2 min). The cell debris was removed by centrifugation at 5,000 rpm for 15 min. A fraction of the supernatant (25 ml) was applied onto a Ni-chelating Sepharose column (1 ml). The column was washed using buffer A which additionally contained 10 mM imidazole. His-tagged polypeptides were eluted in a linear gradient (10 mM-500 mM imidazole in buffer A). Enzyme-containing fractions were pooled. After dialysis against storage buffer (10 mM potassium phosphate, 200 mM KCl, 0.1 mM EDTA, 30 mM mercaptoethanol, 50% glycerol, 0.1% Tween 20, pH 7.9) the pools were stored at −20° C.

Example 4: Analysis of DNA-Dependent RNA Polymerase Activity

A transcription-based non-radioactive assay was used to measure the activity of purified wild-type and variants of T7 RNA polymerase obtained as described in Example 3. The enzyme activity was measured in 40 μl reaction buffer (40 mM Tris/HCl, 6 mM MgCl2, 1 mM NTP (each), 10 mM DTE, 2 mM spermidine, pH 8.0, 1 μg pSPT18 cleaved with SspI). T7 wild-type or T7 variant polymerase enyzme was added in diluted form. After incubation at 37° C. for 30 min. EDTA (0.4 M, 4 μl) was added to stop the reaction. RNA quantification was done using Quant-iT RNA Assay (Invitrogen) on a LC480 Light Cycler platform (Roche Applied Science, Roche Diagnostics GmbH, Mannheim). As a reference enzyme commercially available T7 RNA polymerase was used (Roche Applied Science, Roche Diagnostics GmbH, Mannheim).

Example 5: Analysis of Thermostability: Half-Life Time

To determine the stability of wild-type T7 polymerase and T7 variants the half-life time was determined as a first parameter. Samples of wild-type enzyme and purified variants (see Example 3) were incubated in storage buffer (10 mM potassium phosphate, 200 mM KCl, 0.1 mM EDTA, 30 mM mercaptoethanol, 50% glycerol, 0.1% Tween 20, pH 7.9) at 50° C. At different time points (10, 20 and 30 min) samples were taken and the residual enzyme activity was measured as described in Example 3. The half-life time T1/2 expressed as a number of minutes [min] means that at this time point the activity of the respective T7 variant is 50% of the activity at the time point when the experiment was started, i.e., the exposure to 50° C. was applied. Table 4 summarizes results of the measurements.

TABLE 4 Half-life times at 50° C. of wild-type T7 RNA polymerase and T7 variants (single mutations and combination mutations) # T7 enzyme T1/2 [min] Reference 1 Wild-type 6.0-9.7 Single amino acid substitution 2 Ala319Ser no activity 3 Ala319Val 8.5 4 Ala319Pro no activity 5 Val426Leu 25.0 6 Val426Ile 17.0 7 Val426Phe 12.0 8 Val426Trp 0.4 9 Val629Pro no activity 10 Ser633Val 7.3 11 Ser633Leu 5.3 12 Ser633Met 13.0 13 Val650Leu 13.0 14 Thr654Leu 13.0 15 Ala702Val 22.0 16 Leu705Ile 10.0 17 Leu791Phe no activity 18 Val795Ile 29.0 19 Leu809Phe 7.7 20 Phe814Trp 1.9 21 Met861Trp 5.5 Double amino acid substitution 22 Ala702Val 22.0 Val795Ile 23 Val426Leu 39.0 Ala702Val 24 Val426Leu 40.0 Val795Ile Triple amino acid substitution 25 Val426Leu 312.0 Ala702Val Val795Ile Quadruple amino acid substitution 26 Val426Leu no activity Ser633Met Ala702Val Val795Ile 27 Val426Leu 64.0 Val650Leu Ala702Val Val795Ile Quintuple amino acid substitution 28 Val426Leu no activity Ser633Met Val650Leu Ala702Val Val795Ile

Designations of mutants are the same as in Table 3.

With regards to half-life times at 50° C., the inventors observed several surprising effects. Firstly, there were single amino acid exchanges without noticeable impact on thermostability, i.e., mutations which did not cause a substantial difference compared to the wild-type reference (# 1). In this first group all T7 variants with a T1/2 value between 5 and 12 (including 5 and 12) were combined. The first group comprises the mutations according to ## 3, 7, 10, 11, 16, 19, and 21 as shown in Table 4.

A second group of T7 variants was found in which the mutants had even shorter half-life times at 50° C., compared to the wild-type reference. Additionally, mutants which had lost enzymatic activity completely were combined in the second group. The second group comprises the mutations according to ## 2, 4, 8, 9, 17, 20, 26, and 28 as shown in Table 4.

A third group of amino acid exchange mutations was found to enhance half-life time at 50° C. over the values found for the wild-type reference. A value greater than 12 was considered as indicating a substantial increase of thermostability in the respective T7 variant. The third group comprises the mutations according to ## 5, 6, 12, 13, 14, 15, 18, 22, 23, 24, 25 and 27 as shown in Table 4.

Surprisingly, some amino acid substitutions which, according to theoretical predictions, were predicted to have a desired positive effect on thermostability did not lead to the expected results.

It was noted that mutations at the position Ala319 (see Table 1) belonged to either the first or the second group. According to the theory, these mutations were expected to fill a hydrophobic cavity and thereby increase internal Van-der-Waals forces within the core of the variant T7 polypeptide. Remarkably, the mutation of Ala319 to Val (#3 in Table 4) leaves the RNA polymerase activity intact but without having any noticeable impact on the variant's half-life time at 50° C. But at this position changes to Ser or Pro (#2, #4 in Table 4) abolish enzymatic activity. This finding was interpreted as an indication of more complex intramolecular interactions which impact on the structure and/or enzymatic function of T7 polymerase.

Further results were found at position Val426 which was another candidate residue to be exchanged for generating increased van-der-Waals forces in a cavity of the protein core. In line with the prediction, changing Val426 to Leu, Ile or Phe (#5, #6, #7 in Table 4) produced a variant with enhanced thermostability. But the mutation Val426Trp (#8 in Table 4) unexpectedly destabilized the polymerase enzyme. The same was observed for Leu791Phe (#17 in Table 4) and, although to a somewhat lesser extent, for Phe814Trp (#20in Table 4).

The results obtained for the further mutations Leu705Ile (#16 in Table 4), Leu809Phe (#19 in Table 4) and Met861Trp (#21 in Table 4) did not provide an indication for enhanced thermostability.

Thus, with regards to the approach of increasing van-der-Waals forces in internal hydrophobic cavities, the general theoretical prediction of thermostabilization could not be verified at this point. Rather, the results shown in Table 4 demonstrate that (i) only a subgroup of the sites predicted to be suitable for the desired class of mutations is amenable to amino acid substitutions which actually lead to enhanced thermostability, (ii) there is no means at hand to pre-select this subgroup, and (iii) no prediction can be made which particular amino acid will be effective and produce the desired technical effect.

The same appears to apply to mutations designed to stabilize loop structures. Among six different mutations tested, one (Val629Pro) (#9 in Table 4) completely abolishes enzymatic activity, two (Ser633Val, Ser633Leu; #10 and #11 in Table 4) do not show profound effects, and three (Ser633Met, Val650Leu, and Thr654Leu; #12, #13 and #14 in Table 4) increase thermostability, however not as markedly as mutations of the third group directed to hydrophobic cavities. Again, one position (Ser633; #10, #11, and #12) stands out in that mutations unexpectedly lead to different effects.

Three mutations targeting stabilization of hydrophobic cavities produced results which stood out: Val426Leu, Ala702Val, and Val795Ile (#5, 15, and 18 in Table 4). The three mutations were combined in double and triple mutant variants. Interestingly, all combinations result in functional polymerase enzymes with increased thermostablility when compared with the wild-type reference. Two double mutant combinations (#23 and #24 in Table 4) showed an even further increased thermostability which could be attributed to an additive effect. One double mutant combination (#22 in Table 4) suggests a polar mechanism in that the quantitative effect Ala702Val mutation seems to override the effect of the Val795Ile mutation. However, most strikingly, upon combination of the mutations in a triple mutant a synergistic effect was observed in that thermostability was increased by about one full order of magnitude (#25 in Table 4).

The synergistic effect is further illustrated by the fact that a variant with a quadruple mutant polypeptide which further includes the Val650Leu exchange (#27 in Table 4) shows a further additive effect. Regarding thermostability the effects seen with the quadruple mutant exceeded each of the double mutants but they fail to reach the high value observed with the triple mutant.

A further quadruple and a quintuple mutant variant (#26 and #28 in Table 4) illustrate that it is not possible to deliberately combine further mutations, i.e., that there are effects which render some or all of the combined mutations incompatible.

Example 6: Protein Thermal Unfolding Assay

The stability of wild-type T7 polymerase enzyme and variants of T7 RNA polymerase was further studied by way of determining protein thermal unfolding. The assay was performed essentially as by Yeh, A. P., et al., Acta Cryst. D62 (2006) 451-457, for measuring the unfolding transition of membrane proteins by fluorescent-probe binding in combination with real-time PCR instrumentation and using SYPRO Orange as reporter dye.

Accordingly, all assays were performed using a LC480 LIGHT CYCLER (Roche Applied Science). SYPRO Orange was obtained from Molecular Probes Inc. (Eugene, Oreg., USA) and was diluted 1:10 in DMSO. Protein samples (typically 2 μg) were in Bis-Tris-propane buffer (50-100 mM), pH 8.0 and contained diluted SYPRO Orange (1:1430). Excitation wave length was 483 nm, emission was measured at 568 nm.

Assays were performed in a temperature range starting from 37° C. up to 94° C. with a temperature ramp of 3.6° C./min. Protein thermal unfolding was measured in the absence (Buffer A) or presence (Buffer B) of 50% [v/v] glycerol (see Table 5).

TABLE 5 Protein thermal unfolding, Tm determination # T7 enzyme Tm [° C.] in Buffer A Tm [° C.] in Buffer B Reference 1 Wild-type 50.0 51.5 Single amino acid exchange 5 Val426Leu 52.5 52.5 13 Val650Leu 51.0 n.d. 15 Ala702Val 51.0 n.d. 18 Val795Ile 51.5 n.d. Triple amino acid exchange 25 Val426Leu n.d. (not determined) 55.0 Ala702Val n.d. n.d. Val795Ile n.d. n.d.

Designations of T7 variants are the same as in Table 4.

The data again show that the triple mutant T7 variant #25 exhibits the highest increase of the Tm, compared to the wild-type reference.

Example 7: Determination of Protein Concentration in Solutions

Protein concentrations were determined by measuring the optical density at 280 nm using a molar extinction coefficient of E280 nm=1.4×105 M−1 as described (He, B., et al., Protein Expr Purif 9 (1997) 142-151).

Claims

1. A variant polypeptide of T7 RNA polymerase (T7 variant), the T7 variant having (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference,

wherein the T7 variant comprises a polypeptide of the wild-type reference in which at least one amino acid and up to four amino acids at different positions are substituted,
wherein a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Ser633, Val650, Thr654, Ala702, and Val795, numbered from the N-terminus of the wild-type reference, and
wherein the different amino acid is selected from the group consisting of Leu, Ile and Phe when the different amino acid substitutes for Val426 (Val426Leu, Val426Ile, Val426Phe), Val and Met when the different amino acid substitutes for Ser633 (Ser633Val, Ser633Met), Leu when the different amino acid substitutes for Val650 (Val650Leu), Leu when the different amino acid substitutes for Thr654 (Thr654Leu), Val when the different amino acid substitutes for Ala702 (Ala702Val), and Ile when the different amino acid substitutes for Val795 (Val795Ile).

2-12. (canceled)

13. A method for synthesizing an RNA molecule comprising the steps of

(a) providing a template DNA molecule comprising a T7 promoter, the T7 promoter being functionally linked to a target nucleotide sequence to be transcribed;
(b) contacting the template DNA of step (a) with a variant polypeptide of T7 RNA polymerase (T7 variant) according to claim 1; followed by
(c) incubating the template DNA and the T7 variant in the presence of ribonucleoside triphosphates, thereby synthesizing the RNA molecule.

14-15. (canceled)

Patent History
Publication number: 20160032261
Type: Application
Filed: Oct 16, 2015
Publication Date: Feb 4, 2016
Inventors: Harald Sobek (Penzberg), Johann-Peter Thalhofer (Weilheim), Rainer Mueller (Penzberg), Manfred Schmidt (Penzberg), Michael Greif (Penzberg), Armin Ruf (Freiburg), Christian Rudolph (Penzberg)
Application Number: 14/885,732
Classifications
International Classification: C12N 9/12 (20060101); C12P 19/34 (20060101);